NAAG Works to Prevent the Online Sale of Fraudulent COVID Vaccination Cards

The false and deceptive marketing and sales of fake COVID vaccine cards threaten the health of our communities, slow progress in getting our residents protected from the virus, and are a violation of the laws of many states.

Read More →

Alabama et al. v. Endo International, No. 3:19-cv-04157 (N.D. Cal. July 19, 2019)

Eighteen states reached a settlement with Endo Pharmaceuticals Inc. under which Endo paid $2.3 million to settle allegations it entered into a reverse-payment agreement to obstruct generic competition to Lidoderm, a pain relief patch frequently used to treat shingles. According to the complaint, Endo had an agreement with Watson Laboratories Inc. ensuring Endo would not face…

Read More →

NAAG Sends Letter to USDOJ Condemning January 6 Violence at U.S. Capitol

We all just witnessed a very dark day in America. The events of January 6 represent a direct, physical challenge to the rule of law and our democratic republic itself. Together, we will continue to do our part to repair the damage done to institutions and build a more perfect union. As Americans, and those charged with enforcing the law, we must come together to condemn lawless violence, making clear that such actions will not be allowed to go unchecked.

Read More →

NAAG Asks FDA for Progress Update Under the SUPPORT Act

We have witnessed first-hand the devastation that the opioid epidemic has wrought on states in terms of lives lost and the costs it has imposed on our healthcare system and the broader economy.

Read More →

Settlement Agreement Between Plaintiff States and UBS (Dec. 21, 2018)

Forty plaintiff states reached a $68 million settlement with UBS for fraudulent conduct involving interest rate manipulation that had a significant impact on consumers and financial markets around the world. UBS’ fraudulent conduct involved the manipulation of LIBOR (the London Interbank Offered Rate). LIBOR is a benchmark interest rate that affects financial instruments worth trillions…

Read More →

FTC et al. v. Vyera Pharmaceuticals, No. 1:20-cv-00706 (S.D.N.Y. Apr. 19, 2020)

The FTC, New York and six other states filed suit against Vyera Pharmaceuticals, its parent company, Phoenixus and its former officers, Kevin Mulleady and Martin Shkreli, alleging anticompetivie conduct in connection with Daraprim, the only FDA approved drug for the treatment of the life-threatening parasitic disease toxoplasmosis.  The suit alleges that Vyera purchases the unpatented…

Read More →

Attorneys General Urge Senate to Pass Law to Fight Shell Companies

As our States’ chief legal officers, we are concerned about the use of American financial institutions for money laundering by terrorist groups and other criminal enterprises.

Read More →

NAAG Endorses Stopping Overdoses of Fentanyl Analogues (SOFA) Act

States and localities are on the front line of this crisis and are a large part of winning the battle from both a law enforcement and public health perspective.

Read More →

California et al. v. Teikoku Seikayu Co.(Lidoderm), No. 3:18-cv-00675 (N.D. Cal. 01/31/18)

Plaintiff states alleged that defendant, the producer of Lidoderm (pain medication), paid or incentivized generic drug makers to delay entry into market to protect its monopoly on Lidoderm. (“pay for delay”) The settlement agreement, which expires in twenty years, prohibits Teikoku from entering into agreements that restrict generic drug manufacturers from researching, manufacturing, marketing, or selling products for a period of time and requires Teikoku to cooperate in an ongoing investigation into similarly anticompetitive conduct by other drug manufacturers, among other things.

Read More →

State of Wisconsin et al. v. Indivior, No. 16-5073 (E.D. Pa. Sept. 22,2016)

Plaintiff states alleged that the makers of Suboxone, a drug used to treat opioid addiction, engaged in a scheme to block generic competitors and raise prices. Specifically, they are conspiring to wtich Suboxone from a tablet version to a flim in order to prevent or delay generic entry. The states allege that the manufacturers engaged in “product hopping” in which a company makes slight changes to its product to extend patent protections and prvent generic alternatives. The complaint was filed under seal.

Read More →